Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small molecule medicines for the treatment of inflammatory and fibrotic diseases. It offers Filgotinib medication targeting rheumatoid arthritis (RA). The company is investigating GLPG3667 compound against autoimmune indications; GLPG2737, a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor to treat autosomal dominant polycystic kidney disease; GLPG1690, an oral autotaxin inhibitor targeting idiopathic pulmonary fibrosis (IPF); and GLPG1972 drug to treat osteoarthritis. Galapagos is also evaluating Filgotinib against Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, cutaneous lupus and uveitis. It has operational presence in the Netherlands, France, Germany, Italy, Spain, Switzerland, the United States and the United Kingdom. The company works in collaboration with disease foundations, pharmaceutical and biotechnology companies. Galapagos is headquartered in Mechelen, Belgium.
Headquarters
Belgium
Address
Generaal De Wittelaan 3, Malines (Mechelen), 2800
Website
www.glpg.com
Telephone
32 15 342900
No of Employees
1,305
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLPG (AMS)
Revenue (2021)
$636.9M
1.6%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
66.2%
(2021 vs 2020)
Market Cap*
$3.6B
Net Profit Margin (2021)
XXX
66.7%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products |
|---|
| Pipeline |
| Filgotinib |
| GLPG3667 |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In June, the company agreed to acquire CellPoint and AboundBio. |
| 2022 | Contracts/Agreements | In May, the company exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher’s Spectra platform. |
| 2022 | Contracts/Agreements | In April, the company announced a collaboration with e-therapeutics plc to receive additional milestone payments through pre-clinical and clinical development. |
Competitor Comparison
| Key Parameters | Galapagos NV | TherapeuticsMD Inc | Mithra Pharmaceuticals SA | Oxurion NV | Ablynx NV |
|---|---|---|---|---|---|
| Headquarters | Belgium | United States of America | Belgium | Belgium | Belgium |
| City | Malines (Mechelen) | Boca Raton | Liege | Heverlee | Ghent |
| State/Province | - | Florida | - | - | Flandre Orientale |
| No. of Employees | 1,305 | 416 | 248 | 42 | 450 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Stoffels | Chairman | Executive Board | 2022 | - |
| Bart Filius | President; Chief Financial Officer; Chief Operating Officer | Senior Management | 2021 | 51 |
| Walid Abi-Saab, M.D. | Chief Medical Officer | Senior Management | 2017 | 57 |
| Piet Wigerinck, Ph.D. | Chief Scientific Officer | Senior Management | 2012 | 58 |
| Michele Manto | Chief Commercial Officer | Senior Management | 2020 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer